A multiplex snapback primer system for the enrichment and detection of JAK2 V617F and MPL W515L/K mutations in philadelphia-negative myeloproliferative neoplasms

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Wu, Zhiyuan ^a   Zhang, Yunqing ^b   Zhang, Xinju ^a   Xu, Xiao ^a   Kang, Zhihua ^a   Li, Shibao ^a   Zhang, Chen ^a   Su, Bing ^c   Guan, Ming ^a  

^a FUDAN UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; THROMBOPOIETIN RECEPTOR; GENETIC MARKER; JAK2 PROTEIN, HUMAN; MPL PROTEIN, HUMAN; PRIMER DNA;

ALLELE; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; IONIC STRENGTH; MELTING POINT; MULTIPLEX SNAPBACK PRIMER SYSTEM; MYELOPROLIFERATIVE NEOPLASM; PHILADELPHIA CHROMOSOME NEGATIVE CELL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; GENETIC MARKER; GENETIC SCREENING; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR GENETICS; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; NUCLEOTIDE SEQUENCE; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM;

BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; GENETIC MARKERS; GENETIC TESTING; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR SEQUENCE DATA; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, THROMBOPOIETIN;

EID: 84897849079     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/458457     Document Type: Article

References (40)

1. Vannucchi A. M., Guglielmelli P., Tefferi A., Advances in understanding and management of myeloproliferative neoplasms. CA Cancer Journal for Clinicians 2009 59 3 171 191 2-s2.0-65649088338 10.3322/caac.20009
2. Levine R. L., Wadleigh M., Cools J., Ebert B. L., Wernig G., Huntly B. J. P., Boggon T. J., Wlodarska I., Clark J. J., Moore S., Adelsperger J., Koo S., Lee J. C., Gabriel S., Mercher T., D'Andrea A., Fröhling S., Döhner K., Marynen P., Vandenberghe P., Mesa R. A., Tefferi A., Griffin J. D., Eck M. J., Sellers W. R., Meyerson M., Golub T. R., Lee S. J., Gilliland D. G., Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005 7 4 387 397 2-s2.0-20244369569 10.1016/j.ccr.2005.03.023 (Pubitemid 40544655)
3. Baxter E. J., Scott L. M., Campbell P. J., Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. The Lancet 2005 365 1054 1061 (Pubitemid 40386783)
4. Jones A. V., Kreil S., Zoi K., Waghorn K., Curtis C., Zhang L., Score J., Seear R., Chase A. J., Grand F. H., White H., Zoi C., Loukopoulos D., Terpos E., Vervessou E.-C., Schultheis B., Emig M., Ernst T., Lengfelder E., Hehlmann R., Hochhaus A., Oscier D., Silver R. T., Reiter A., Cross N. C. P., Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005 106 6 2162 2168 2-s2.0-21344467318 10.1182/blood-2005-03-1320 (Pubitemid 41291734)
5. Kralovics R., Passamonti F., Buser A. S., Teo S.-S., Tiedt R., Passweg J. R., Tichelli A., Cazzola M., Skoda R. C., A gain-of-function mutation of JAK2 in myeloproliferative disorders. The New England Journal of Medicine 2005 352 17 1779 1790 2-s2.0-17644424955 10.1056/NEJMoa051113 (Pubitemid 40570926)
6. Pikman Y., Lee B. H., Mercher T., McDowell E., Ebert B. L., Gozo M., Cuker A., Wernig G., Moore S., Galinsky I., DeAngelo D. J., Clark J. J., Lee S. J., Golub T. R., Wadleigh M., Gilliland D. G., Levine R. L., MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Medicine 2006 3, article e270 2-s2.0-33746437130 10.1371/journal.pmed.0030270 (Pubitemid 44125998)
7. Pardanani A. D., Levine R. L., Lasho T., Pikman Y., Mesa R. A., Wadleigh M., Steensma D. P., Elliott M. A., Wolanskyj A. P., Hogan W. J., McClure R. F., Litzow M. R., Gilliland D. G., Tefferi A., MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006 108 10 3472 3476 2-s2.0-33750534561 10.1182/blood-2006-04-018879
8. Swerdllow S., Campo E., Harris N. L., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008 Lyon, France IARC Press
9. Huang M.-M., Arnheim N., Goodman M. F., Extension of base mispairs by Taq DNA polymerase: implications for single nucleotide discrimination in PCR. Nucleic Acids Research 1992 20 17 4567 4573 2-s2.0-0026698636
10. Beer P. A., Jones A. V., Bench A. J., Goday-Fernandez A., Boyd E. M., Vaghela K. J., Erber W. N., Odeh B., Wright C., McMullin M. F., Cullis J., Huntly B. J. P., Harrison C. N., Cross N. C. P., Green A. R., Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. British Journal of Haematology 2009 144 6 904 908 2-s2.0-60649096136 10.1111/j.1365-2141.2008.07560.x
11. Loeb L. A., Loeb K. R., Anderson J. P., Multiple mutations and cancer. Proceedings of the National Academy of Sciences of the United States of America 2003 100 3 776 781 2-s2.0-0037417954 10.1073/pnas.0334858100 (Pubitemid 36183906)
12. Warshawsky I., Mularo F., Hren C., Jakubowski M., Failure of the Ipsogen MutaScreen kit to detect the JAK2 617V>F mutation in samples with additional rare exon 14 mutations: implications for clinical testing and report of a novel 618C>F mutation in addition to 617V>F. Blood 2010 115 15 3175 3176 2-s2.0-77951070801 10.1182/blood-2009-12-257501
13. Zhou L., Palais R. A., Denice Smith G., Anderson D., Rowe L. R., Wittwer C. T., Enrichment and detection of rare alleles by means of snapback primers and rapid-cycle PCR. Clinical Chemistry 2010 56 5 814 822 2-s2.0-77951752783 10.1373/clinchem.2009.142034
14. Ho S. N., Hunt H. D., Horton R. M., Pullen J. K., Pease L. R., Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989 77 1 51 59 2-s2.0-0024520745 (Pubitemid 19125653)
15. Sanchez J. A., Pierce K. E., Rice J. E., Wangh L. J., Linear-After-The-Exponential (LATE)-PCR: an advanced method of asymmetric PCR and its uses in quantitative real-time analysis. Proceedings of the National Academy of Sciences of the United States of America 2004 101 1933 1938 (Pubitemid 38228993)
16. Zhuge J., Zhang W., Xu M., Hoffman R., Zhang W., Sensitive detection of MPLW515L/K mutations by amplification refractory mutation system (ARMS)-PCR. Clinica Chimica Acta 2010 411 1-2 122 123 2-s2.0-70449530413 10.1016/j.cca.2009.10.012
17. Wolstencroft E. C., Hanlon K., Harries L. W., Standen G. R., Sternberg A., Ellard S., Development of a quantitative real-time polymerse chain reaction assay for the detection of the JAK2 V617F mutation. Journal of Molecular Diagnostics 2007 9 1 42 46 2-s2.0-33947541474 10.2353/jmoldx.2007.060083 (Pubitemid 47322012)
18. Pancrazzi A., Guglielmelli P., Ponziani V., Bergamaschi G., Bosi A., Barosi G., Vannucchi A. M., A sensitive detection method for WPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. Journal of Molecular Diagnostics 2008 10 5 435 441 2-s2.0-52249100940 10.2353/jmoldx.2008. 080015
19. Tefferi A., Vardiman J. W., Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008 22 1 14 22 2-s2.0-38349101871 10.1038/sj.leu.2404955
20. Vardiman J. W., Thiele J., Arber D. A., Brunning R. D., Borowitz M. J., Porwit A., Harris N. L., Le Beau M. M., Hellström-Lindberg E., Tefferi A., Bloomfield C. D., The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009 114 5 937 951 2-s2.0-70349256226 10.1182/blood-2009-03- 209262
21. Thiele J., Kvasnicka H. M., The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Current hematologic malignancy reports 2009 4 1 33 40 2-s2.0-77955063840 10.1007/s11899-009-0005-6
22. Harrison C., Kiladjian J.-J., Al-Ali H. K., Gisslinger H., Waltzman R., Stalbovskaya V., McQuitty M., Hunter D. S., Levy R., Knoops L., Cervantes F., Vannucchi A. M., Barbui T., Barosi G., JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. The New England Journal of Medicine 2012 366 9 787 798 2-s2.0-84857837774 10.1056/NEJMoa1110556
23. Verstovsek S., Mesa R. A., Gotlib J., Levy R. S., Gupta V., DiPersio J. F., Catalano J. V., Deininger M., Miller C., Silver R. T., Talpaz M., Winton E. F., Harvey J. H. Jr., Arcasoy M. O., Hexner E., Lyons R. M., Paquette R., Raza A., Vaddi K., Erickson-Viitanen S., Koumenis I. L., Sun W., Sandor V., Kantarjian H. M., A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine 2012 366 9 799 807 2-s2.0-84857803734 10.1056/NEJMoa1110557
24. Bai R.-K., Wong L.-J. C., Detection and quantification of heteroplasmic mutant mitochondrial DNA by real-time amplification refractory mutation system quantitative PCR analysis: a single-step approach. Clinical Chemistry 2004 50 6 996 1001 2-s2.0-2642539211 10.1373/clinchem.2004.031153 (Pubitemid 38725786)
25. Schnittger S., Bacher U., Kern W., Schröder M., Haferlach T., Schoch C., Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia 2006 20 12 2195 2197 2-s2.0-33751234537 10.1038/sj.leu.2404325 (Pubitemid 44782853)
26. Wong C., Ma E., Wang C., Lam H., Ma S., JAK2 V617F due to a novel TG→CT mutation at nucleotides 1848-1849: diagnostic implication. Leukemia 2007 21 1344 1346 (Pubitemid 46831835)
27. Mead A. J., Rugless M. J., Jacobsen S. E. W., Schuh A., Germline JAK2 mutation in a family with hereditary thrombocytosis. The New England Journal of Medicine 2012 366 10 967 969 2-s2.0-84857863366
28. Boyd E. M., Bench A. J., Goday-Fernández A., Anand S., Vaghela K. J., Beer P., Scott M. A., Bareford D., Green A. R., Huntly B., Erber W. N., Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis: research paper. British Journal of Haematology 2010 149 2 250 257 2-s2.0-77949810252 10.1111/j.1365-2141.2010. 08083.x
29. Chaligné R., Tonetti C., Besancenot R., Roy L., Marty C., Mossuz P., Kiladjian J.-J., Socié G., Bordessoule D., Le Bousse-Kerdilès M.-C., Vainchenker W., Giraudier S., New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia 2008 22 8 1557 1566 2-s2.0-49449094277 10.1038/leu.2008.137
30. Zhou L., Errigo R. J., Lu H., Poritz M. A., Seipp M. T., Wittwer C. T., Snapback primer genotyping with saturating DNA dye and melting analysis. Clinical Chemistry 2008 54 10 1648 1656 2-s2.0-54049108161 10.1373/clinchem. 2008.107615
31. Farrar J. S., Palais R. A., Wittwer C. T., Snapback primer genotyping of the Gilbert syndrome UGT1A1 (TA)n promoter polymorphism by high-resolution melting. Clinical Chemistry 2011 57 9 1303 1310 2-s2.0-80052235994 10.1373/clinchem.2011.166306
32. Witt M., Dawidowska M., Szczepanski T., Molecular Aspects of Hematologic Malignancies 2012
33. Cankovic M., Whiteley L., Hawley R. C., Zarbo R. J., Chitale D., Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods. American Journal of Clinical Pathology 2009 132 5 713 721 2-s2.0-70449713792 10.1309/ AJCPFHUQZ9AGUEKA
34. Qian J., Lin J., Yao D.-M., Chen Q., Xiao G.-F., Ji R.-B., Li Y., Yang J., Qian Z., Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform. Clinica Chimica Acta 2010 411 23-24 2097 2100 2-s2.0-77957752388 10.1016/j.cca.2010.08.020
35. Ivanova M. I., Shivarov V. S., Hadjiev E. A., Naumova E. J., Novel multiplex bead-based assay with LNA-modified probes for detection of MPL exon 10 mutations. Leukemia Research 2011 35 8 1120 1123 2-s2.0-79960236079 10.1016/j.leukres.2011.04.012
36. Schnittger S., Bacher U., Eder C., Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow. Haematologica 2012 97 1582 1585
37. Wittwer C. T., Reed G. H., Gundry C. N., Vandersteen J. G., Pryor R. J., High-resolution genotyping by amplicon melting analysis using LCGreen. Clinical Chemistry 2003 49 6 853 860 2-s2.0-0038359432 10.1373/49.6.853 (Pubitemid 36623462)
38. Pietra D., Brisci A., Rumi E., Boggi S., Elena C., Pietrelli A., Bordoni R., Ferrari M., Passamonti F., de Bellis G., Cremonesi L., Cazzola M., Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica 2011 96 4 607 611 2-s2.0-79953890796 10.3324/haematol.2010.034793
39. Wu Z., Yuan H., Zhang X., Liu W., Xu J., Zhang W., Guan M., Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera. PLoS ONE 2011 6 10 2-s2.0-80054777529 10.1371/journal.pone.0026534 e26534
40. Wittwer C. T., Garling D. J., Rapid cycle DNA amplification: time and temperature optimization. BioTechniques 1991 10 1 76 83 2-s2.0-0025965114